Quillivant XR

METHYLPHENIDATES · EXTENDED-RELEASE ORAL SUSPENSION

BRAND GENERIC APPROVED · SOURCES DIFFER AVAILABLE (ASHP)
STIMULANT · SCHEDULE II · REVIEWED NOV 2026
Reviewed by Tariq Halim, MD — ABPN Board-Certified General Psychiatrist · Editorial policy
Last medical review: November 12, 2026
Tariq Halim, MD reports no conflicts of interest. Contact

Key facts

Drug class
CNS Stimulant · Methylphenidates
Active ingredient
methylphenidate hydrochloride
FDA-approved ages
6 years and older
Form and strengths
Extended-release oral suspension; 25 mg per 5 mL (after pharmacist reconstitution)
Usual dose and maximum (label)
Start 20 mg once daily in the morning; doses above 60 mg/day are not recommended.
Duration
Benefit from 45 minutes through 12 hours in a children’s classroom study.
DEA schedule
Schedule II controlled substance (CII)
Generic
Generic approved · sources differ (see Generic manufacturers)
Label date
Prescribing Information revised 03/2026 (DailyMed)

Label last checked: Oct 2026 — Prescribing Information revised 03/2026 (DailyMed) · Last medical review: November 12, 2026

Educational information only, not medical advice. Do not start, stop or change a medication without your prescriber. Medical disclaimer

Quillivant XR is a once-daily long-acting methylphenidate liquid. The pharmacist mixes the powder with water to make a 25 mg per 5 mL suspension, which is shaken and measured with an oral dosing dispenser each morning. About 20% is immediate-release and 80% extended-release; in its classroom study it worked from 45 minutes through 12 hours. It is approved for ages 6 and older, and ASHP lists it as available.

What it is

Quillivant XR is a long-acting liquid form of methylphenidate taken once in the morning. It is measured with the dosing dispenser that comes with it, which makes it useful for people who cannot swallow pills or need small dose changes. It can help with focus, staying on task, and reducing hyperactivity and impulsivity through the day.

Methylphenidate HCl ER powder for oral suspension; after pharmacist reconstitution, 25 mg/5 mL (each mL = 5 mg methylphenidate HCl, present as 4.32 mg methylphenidate complexed with sodium polystyrene sulfonate), ~20% immediate-release and ~80% extended-release. Median Tmax ~4–5 h; half-life ~5.0–5.2 h (children, adolescents, adults) and 5.6 h in fasted adults. Indicated for ADHD in patients 6 years and older (label revised 03/2026; manufactured by Tris Pharma). Schedule II. Orange Book AB; the Orange Book lists an AB-rated generic (Actavis, ANDA 206049) as RX, while the FDA NDC Directory and DailyMed list no product under it (checked Oct 29, 2026).

When considering this for a patient

Quillivant XR offers once-daily liquid dosing with fine titration and a long studied effect window (significant at 0.75, 2, 4, 8, 10, and 12 hours in the classroom study). The bottle must be shaken vigorously for at least 10 seconds before each dose, and the reconstituted suspension is stable for up to 4 months.

Write doses in milligrams and confirm the dispenser volume with caregivers to avoid measurement errors. Schedule II with a boxed warning for abuse, misuse, and addiction; screen for cardiac disease and tics, and monitor appetite, sleep, growth, blood pressure, and heart rate.

Patient profile and niche

Quillivant XR may be particularly useful in the following situations:

  • Patients who cannot or prefer not to swallow tablets or capsules.
  • Need for flexible liquid dosing or small titration increments.
  • Children or adults who respond to methylphenidate and need once-daily coverage.

When it is active

Quillivant XR usually starts working within about 45 minutes. Blood levels peak about 4–5 hours after the dose. In the classroom study, benefit was significant at 45 minutes and at 2, 4, 8, 10, and 12 hours after dosing.

Use the interactive tool below to align the typical Quillivant XR profile with your schedule. The curve is a schematic based on labeling data, not a prediction for any individual.

YOUR DAY WITH QUILLIVANT XR

Enter the times that match your (or your child’s) typical day. The curve shows relative plasma level over clock time.

Typical Quillivant XR · Starts working in about 45 minutes · Peak about 4–5 hours after the dose · Studied benefit through about 12 hours · Wearing off after that
The curve shows relative plasma concentration (not guaranteed clinical effect).
Average half-life is about 5–5.6 hours.
Everyone is different. This is a general guide based on labeling data, not a prediction for any one person.
Relative plasma level schematic (not to clinical scale) from Quillivant XR labeling (Section 12.3): median Tmax ~4–5 h after a 60 mg dose; t1/2 5.2 h (children), 5.0 h (adolescents), 5.2 h (adults), and 5.6 h in fasted adults. Pediatric laboratory classroom (Section 14): SKAMP-Combined significantly improved at 0.75, 2, 4, 8, 10, and 12 h post-dose. Individual curves vary.

How it works

Schematic of methylphenidate mechanism: DAT and NET reuptake blockade
Methylphenidate blocks DAT and NET, reducing reuptake of dopamine and norepinephrine; labeling also describes increased release of these monoamines into the extraneuronal space.

Methylphenidate blocks the transporters that normally remove dopamine and norepinephrine from the synapse, increasing their availability in brain areas involved in attention and impulse control. In Quillivant XR, most of the medicine is bound to resin particles that release it gradually.

DAT Dopamine transporter blockade
Increases synaptic dopamine
NET Norepinephrine transporter blockade
Increases synaptic norepinephrine
IMMEDIATE (~20%) Released soon after the dose
Starts the effect
EXTENDED (~80%) Resin-bound methylphenidate
Peak about 4–5 hours after the dose

Per labeling, the mode of therapeutic action in ADHD is not known. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space. Methylphenidate is racemic; the d-isomer is more active.

Formulations and duration

Once-daily liquid taken in the morning with or without food. Shake the bottle vigorously for at least 10 seconds before each dose and measure with the oral dosing dispenser provided.

STRENGTH25 mg per 5 mL (after pharmacist reconstitution)
BOTTLE SIZES300, 600, 750, 900 mg (60, 120, 150, 180 mL)
APPROVED AGES6 years and older
ADMINISTRATIONOnce daily in the morning; shake ≥10 seconds; measure with oral dosing dispenser
AVAILABILITYBrand listed as available (ASHP Oct 14, 2026); AB generic listed as RX in the Orange Book but with no NDC Directory or DailyMed listing (checked Oct 29, 2026)

Appearance

Quillivant XR is a liquid, so identification relies on the carton and bottle label (FDA label):

  • Reconstituted suspension: 25 mg methylphenidate HCl per 5 mL
  • Each carton contains one bottle, one oral dosing dispenser, and one bottle adapter
  • Stable for up to 4 months after reconstitution; store at 25°C (77°F)

The product must be reconstituted only by the pharmacist, not by the patient or caregiver.

Official package photos and pill identifiers:

Generic manufacturers

The FDA Orange Book lists one generic methylphenidate ER oral suspension, from Actavis Laboratories FL (Teva), rated AB to Quillivant XR and approved in May 2018, as an active prescription product. As of Oct 29, 2026, neither the FDA NDC Directory nor DailyMed lists a product under that approval, and ASHP lists only brand Quillivant XR among extended-release suspensions. Ask your pharmacy whether a generic can be ordered.

ManufacturerNotes
Tris Pharma (NextWave)Brand Quillivant XR (NDA 202100); listed as marketed on DailyMed, NDC 24478-0321 to -0324
Actavis Laboratories FL (Teva)AB-rated ANDA 206049, approved May 17, 2018; Orange Book RX; no NDC Directory or DailyMed listing (checked Oct 29, 2026)

Orange Book (ANDA 206049 and NDA 202100 rechecked Oct 29, 2026; data file dated Oct 9, 2026, unchanged): Quillivant XR (NDA 202100, NextWave/Tris) RX/AB; Actavis Labs FL ANDA 206049 (5 mg/mL) RX/AB, approved May 17, 2018. DailyMed and NDC Directory (checked Oct 29, 2026): the Quillivant XR label (SPL version 21, revised 03/2026) lists all four packages as marketed with no end date; a DailyMed search (database published Oct 28, 2026) finds no Actavis or Teva suspension label; the FDA NDC Directory (openFDA data updated Oct 28, 2026) lists only the four Quillivant XR NDCs (NDA 202100) and nothing under ANDA 206049. ASHP (Methylphenidate Extended Release Oral Presentations, updated Oct 14, 2026; checked Oct 29, 2026): Tris Pharma Quillivant XR 60, 120, 150 and 180 mL bottles (NDC 24478-0321 to -0324) available; no other extended-release suspension listed. These sources are maintained separately and can disagree.

Common side effects

Most side effects are mild and often improve after the first few weeks. Common ones include decreased appetite, trouble sleeping, stomach upset, and mood changes.

EFFECTFREQUENCYNOTES
Decreased appetite / weight lossCommonWeight and growth are checked
Trouble sleepingCommonTake at the labeled time of day
Nausea, vomiting, or stomach acheCommonTell your clinician if it persists
Anxiety or irritabilityCommonReport mood changes
DizzinessCommonUsually mild
Fast heartbeat / higher blood pressureCommonMonitored routinely

Based on accumulated data from other methylphenidate products, the label lists the most common (≥5% and twice placebo) adverse reactions as appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, and blood pressure increased. Boxed warning for abuse, misuse, and addiction; assess risk before prescribing and reassess during treatment. Warnings include risks to patients with serious cardiac disease, increased blood pressure and heart rate, psychiatric adverse reactions (screen for mania risk), priapism, peripheral vasculopathy including Raynaud’s phenomenon, long-term suppression of growth in pediatric patients, acute angle-closure glaucoma, increased intraocular pressure, and motor and verbal tics/worsening of Tourette’s syndrome. Contraindicated with MAOIs or within 14 days of stopping an MAOI. Monitor blood pressure, heart rate, height, and weight at baseline and periodically.

Misuse context (outside the label): in SAMHSA’s 2023 National Survey on Drug Use and Health, 1.4% of people aged 12 or older (about 3.9 million) misused a prescription stimulant in the past year; the rate was highest in adults aged 18 to 25 (3.1%). The survey counts all prescription stimulants (amphetamine and methylphenidate products, weight-loss stimulants and others), not this medicine alone (SAMHSA, 2023 NSDUH).

Dosing considerations

Most people start at 20 mg (4 mL) once in the morning, and the dose is increased weekly if needed. Always shake the bottle well and use the oral dosing dispenser.

Recommended starting dose for patients 6 years and older: 20 mg once daily in the morning, with or without food; increase weekly by 10–20 mg/day; daily dosage above 60 mg is not recommended. Vigorously shake the bottle for at least 10 seconds before each dose. Reconstitution is performed by the pharmacist only.

Baseline ECG: The label’s pre-treatment cardiac assessment is a careful history, including family history of sudden death or ventricular arrhythmia, and a physical exam; it does not call for a routine ECG. NICE NG87 states that an ECG is not needed before starting stimulants unless a feature listed in 1.7.5 is present (e.g., congenital heart disease or previous cardiac surgery, sudden cardiac death in a first-degree relative under 40, exertional breathlessness or syncope, paroxysmal palpitations, cardiac-sounding chest pain, signs of heart failure, a murmur, or adult hypertension) or a co-existing condition is treated with a medicine that adds cardiac risk; those features call for a cardiology opinion (1.7.4–1.7.5). The AAP 2019 guideline asks for a history of cardiac symptoms and a family history of sudden death, WPW, hypertrophic cardiomyopathy and long QT, with further evaluation if any risk factor is present. A Canadian joint position statement (Warren 2009) and the European ADHD Guidelines Group (Graham 2011) do not recommend routine ECG screening; Graham notes that the American Heart Association’s 2008 statement first proposed an ECG as standard and then left it to clinician discretion. In one US screening series, 8.1% of ECGs were abnormal but heart disease was found in 0.3% (Mahle 2009).

Planned breaks from medicine (weekends and holidays)

Some families leave out doses on weekends or during school holidays. This is sometimes called a medication holiday or treatment break. Plan any break with the prescriber instead of stopping on your own.

Breaks are usually considered for poor appetite, slow weight gain, trouble sleeping, slowed growth, or to see whether the medicine is still needed. The label says children who are not growing or gaining weight as expected may need to have treatment paused.

In studies, breaks helped appetite, sleep and weight gain. It is less clear that they help a child end up taller: one older study saw a height benefit only after two summers off, and a newer trial found that weekend breaks did not speed up height growth. ADHD symptoms can return on days off, so breaks tend to suit lower-pressure times. If you try one, watch how things go at home and with friends, and restart if problems come back.

Growth warning (label 5.7): monitor height and weight during treatment of pediatric patients; those not growing or gaining height or weight as expected may need treatment interrupted. NICE NG87 lists a planned break among options when weight loss is a concern (1.8.6), suggests considering a break over school holidays to allow catch-up growth when height is significantly affected (1.8.7), and advises periodic trial periods off medication or at a lower dose when the balance of benefit and harm suggests it (1.10.3). The AACAP 2007 practice parameter suggests considering a holiday when height or weight crosses two percentile lines, provided off-medication weekends or summers are not markedly impairing, and regards low-stress periods such as vacations (not the start of a school year) as a good time for a discontinuation trial.

Evidence (see Clinical evidence: Growth, below): in a 4-week RCT of twice-daily IR methylphenidate, weekend placebo reduced insomnia without a significant rise in weekend parent or Monday teacher ratings (Martins 2004, n=40). In children with stimulant-associated weight loss, school-days-only dosing increased weight velocity but not height velocity, and most families in that arm resumed after-school dosing because of symptoms (Waxmonsky 2020). Two summers off methylphenidate were followed by a height benefit; one summer was not (Klein 1988). A review of 22 studies found 25–70% of families use breaks (Ibrahim 2015). In the observational MTA follow-up, consistent long-term use was associated with about 2.4 cm lower adult height (Swanson 2017). Data in adults are sparse.

Pregnancy and breastfeeding

Tell your clinician if you are pregnant, plan to become pregnant, or are breastfeeding. There is not enough information to know whether methylphenidate raises the risk of birth defects, miscarriage, or other problems in pregnancy. Stimulant medicines can narrow blood vessels, which may reduce blood flow to the placenta.

Outside the label: in one very large study of US and Nordic pregnancy records, methylphenidate taken in the first 3 months of pregnancy was linked to a possible small increase in heart defects, while the overall rate of birth defects was not significantly higher. Absolute risks stayed low. See Clinical evidence from published studies (Pregnancy) below.

Small amounts of methylphenidate pass into breast milk. No harm to breastfed babies and no effect on milk supply have been reported, but long-term effects are not known. If you breastfeed while taking Quillivant XR, decide together with your clinician, and watch the baby for agitation, poor sleep, poor feeding, or slow weight gain.

A national pregnancy registry collects information about ADHD medicines used during pregnancy. You or your clinician can enroll by calling 1-866-961-2388.

Pregnancy (label 8.1): limited published studies and small case series of methylphenidate in pregnant women are insufficient to inform any drug-associated risks. Clinical considerations: CNS stimulants can cause vasoconstriction and thereby decrease placental perfusion; no fetal or neonatal adverse reactions have been reported with therapeutic doses of methylphenidate, but premature delivery and low birth weight have been reported in infants of amphetamine-dependent mothers. Animal data: no teratogenic effects in rats and rabbits at 2 and 11 times the MRHD; spina bifida in rabbits at about 40 times the MRHD. Registry: National Pregnancy Registry for Psychostimulants (as named in the label), 1-866-961-2388.

Lactation (label 8.2): limited published data (limited published literature) show methylphenidate in human milk at infant doses of 0.16% to 0.7% of the maternal weight-adjusted dose and a milk/plasma ratio of 1.1 to 2.7, with no reported adverse effects in breastfed infants and no effects on milk production; long-term neurodevelopmental effects are unknown. Weigh the benefits of breastfeeding against the mother’s clinical need for Quillivant XR and any potential effects on the infant. Monitor breastfed infants for agitation, insomnia, anorexia, and reduced weight gain.

Outside the label (InPreSS; Huybrechts 2018, JAMA Psychiatry; PubMed 29238795): first-trimester methylphenidate in a US Medicaid cohort of 1,813,894 pregnancies, adjusted RR for any congenital malformation 1.11 (95% CI 0.91–1.35), not significant; cardiac malformations 1.28 (0.94–1.74) in the US cohort and 1.28 (1.00–1.64) when pooled with a Nordic cohort of 2,560,069 pregnancies. Amphetamines showed no increase (any malformation 1.05, cardiac 0.96). These are observational findings; they do not change the label’s section 8.1 statement.

Outside the label: LactMed (NCBI Bookshelf, “Methylphenidate,” revised Aug 2025; NBK501310) says milk levels at prescribed doses appear very low and were not detectable in infant blood, that needing methylphenidate is not a reason to stop breastfeeding, and that large doses might reduce milk production, especially before lactation is well established. This is LactMed’s summary of published data, not FDA label content.

Availability and shortages

AVAILABLE (ASHP) · SOURCES DIFFER ON GENERIC Sources disagree about whether a generic Quillivant XR is sold. As of Oct 29, 2026: the FDA Orange Book lists one AB-rated generic (Actavis Laboratories FL, ANDA 206049, approved in 2018) as an active prescription product; the FDA NDC Directory and DailyMed list no product under that application; ASHP lists brand Quillivant XR in all four bottle sizes as available and lists no generic suspension; and the FDA Drug Shortages database has no entry for methylphenidate suspension. We list what each source reports and do not decide between them.

Before a refill, ask your pharmacy which versions it can currently order, and talk with your prescriber before switching to a different product.

Because it is mixed (reconstituted) at the pharmacy, allow time for preparation.

Sources rechecked Oct 29, 2026. They disagree, and none is treated here as definitive. Orange Book (ANDA 206049 and NDA 202100 rechecked Oct 29, 2026; data file dated Oct 9, 2026, unchanged): Quillivant XR (NDA 202100, NextWave/Tris) RX/AB; Actavis Labs FL ANDA 206049 (5 mg/mL) RX/AB, approved May 17, 2018. FDA Drug Shortages (database, checked Oct 29, 2026): no methylphenidate suspension entry. ASHP (Methylphenidate Extended Release Oral Presentations, updated Oct 14, 2026; checked Oct 29, 2026): Tris Pharma Quillivant XR 60, 120, 150 and 180 mL bottles (NDC 24478-0321 to -0324) available; no other extended-release suspension listed. DailyMed and NDC Directory (checked Oct 29, 2026): the Quillivant XR label (SPL version 21, revised 03/2026) lists all four packages as marketed with no end date; a DailyMed search (database published Oct 28, 2026) finds no Actavis or Teva suspension label; the FDA NDC Directory (openFDA data updated Oct 28, 2026) lists only the four Quillivant XR NDCs (NDA 202100) and nothing under ANDA 206049. These sources are maintained separately and updated on different schedules. Confirm what the dispensing pharmacy can obtain before prescribing or switching.

How Quillivant XR compares to other methylphenidates

Quillivant XR is one of several methylphenidate-family options. Effect windows below come from each product’s FDA labeling (clinical study time points), not head-to-head comparisons; individual duration varies.

Medication Studied effect window / dosing (label) Release design Key practical notes
Quillivant XR (oral suspension) Significant from 0.75 h through 12 h ~20% immediate + ~80% extended release Liquid 25 mg/5 mL after reconstitution; shake before each dose.
Methylin (oral solution) Short-acting; dosed 2–3 times daily Immediate-release liquid Grape-flavored solution for patients who cannot swallow tablets.
QuilliChew ER (chewable) Significant at 0.75, 2, 4 and 8 h (assessed to 13 h) ~30% immediate + ~70% extended release Chewable; 20 and 30 mg tablets scored.
Cotempla XR-ODT (disintegrating tablet) Significant 1–12 h after dosing ~25% immediate + ~75% extended release Dissolves in mouth; ages 6–17. Authorized generic exists.
Concerta (OROS tablet) Effects maintained through 12 h after dosing Osmotic tablet: drug overcoat + gradual osmotic delivery Swallow whole. AB-rated generics. ER tablets on FDA shortage list (brand reported available).
Focalin XR (dexmethylphenidate beads) Significant from 0.5 h through 12 h (pediatric studies) 50% immediate + 50% delayed-release beads, d-isomer Sprinkle allowed. AB generics; ER capsules on ASHP shortage list.

Other methylphenidate-family pages: Concerta, Ritalin, Methylin, Ritalin LA, Metadate CD, Aptensio XR, Adhansia XR, Focalin, Focalin XR, Azstarys, Jornay PM, Cotempla XR-ODT, QuilliChew ER, Daytrana, Relexxii, Methylphenidate ER tablets (10/20 mg), Methylphenidate chewable tablets.

Clinical evidence from published studies

These findings come from published research, not from the FDA label. The FDA label is the official source for approved uses, doses and warnings. Results from studies may not apply to you. Uses marked off-label are not FDA-approved. Talk with your prescriber before making any change.

Items summarize peer-reviewed publications, checked against the PubMed abstract (or full text where stated); figures are reproduced only where the source states them. The FDA label governs approved indications and dosing. Off-label items are not FDA-approved uses. Industry funding or sponsor affiliation is noted where the PubMed record shows it; absence of a note does not mean no industry involvement.

Studies of this medicine (1 study)
  • Randomized controlled trial

    Quillivant XR

    In a classroom study, Quillivant XR improved attention and behavior from 45 minutes through 12 hours after the dose compared with placebo.

    Lab-classroom RCT (completers n=39). SKAMP-Combined at 4 h 7.12 vs 19.58 (p<0.0001); significant at 0.75, 2, 4, 8, 10 and 12 h. Open-label AEs: decreased appetite 55.6%, upper abdominal pain 42.2%.

    Wigal SB, Childress AC, Belden HW, et al. (2013). NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J Child Adolesc Psychopharmacol 23(1):3-10. DOI · PubMed 23289899

How ADHD medicines compare (6 studies)
  • Network meta-analysis

    ADHD medicines (class)

    A large analysis of 133 short-term trials found that every ADHD medicine studied worked better than placebo on clinician ratings in children and teens. Amphetamines had the largest average effect, and methylphenidate was the only medicine also shown to beat placebo on teacher ratings. Amphetamines and guanfacine led to more stopping for side effects than placebo in children. Weighing benefit and side effects, the authors favored methylphenidate first in children and amphetamines first in adults. There was too little data to judge effects beyond about 12 weeks.

    Network meta-analysis of 133 double-blind RCTs (efficacy near 12 wk: 10,068 children/adolescents; 8,131 adults). Children, clinician-rated SMD vs placebo: amphetamines −1.02 (95% CI −1.19 to −0.85), methylphenidate −0.78 (−0.93 to −0.62), atomoxetine −0.56 (−0.66 to −0.45). Teacher-rated: only methylphenidate (−0.82, −1.16 to −0.48) and modafinil separated from placebo. Adults, clinician-rated: amphetamines −0.79 (−0.99 to −0.58), methylphenidate −0.49 (−0.64 to −0.35), atomoxetine −0.45 (−0.58 to −0.32). Discontinuation for adverse events vs placebo: amphetamines OR 2.30 (1.36–3.89) in children and 3.26 (1.54–6.92) in adults; guanfacine 2.64 (1.20–5.81) in children; atomoxetine 2.33 (1.28–4.25) and methylphenidate 2.39 (1.40–4.08) in adults only. Head-to-head clinician-rated efficacy favored amphetamines over methylphenidate, atomoxetine and modafinil. Insufficient data at 26 and 52 weeks.

    Funding / affiliation: Non-industry (Stichting Eunethydis; UK NIHR Oxford Health BRC).

    Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727-738. DOI · PubMed 30097390

  • Network meta-analysis

    ADHD treatments in children and teens (class)

    Across 190 trials in children and teens, methylphenidate, amphetamine, atomoxetine, guanfacine and clonidine all worked better than placebo. Methylphenidate and amphetamine appeared more effective than atomoxetine and guanfacine. Behavioral therapy combined with a stimulant appeared better than either medicine type alone. Most effective medicines also caused harms such as reduced appetite, weight loss and sleep problems.

    Bayesian network meta-analyses of 190 RCTs (52 interventions, 26,114 participants; ≥3 weeks follow-up). Medications more efficacious than placebo: methylphenidate, amphetamine, atomoxetine, guanfacine, clonidine. Methylphenidate and amphetamine more efficacious than atomoxetine and guanfacine; methylphenidate and clonidine better accepted (all-cause discontinuation) than placebo and atomoxetine. Behavioural therapy plus stimulants appeared superior to stimulants or nonstimulants alone. Harms included anorexia, weight loss and insomnia. Results expressed as ORs with credible intervals (not reproduced here).

    Catalá-López F, Hutton B, Núñez-Beltrán A, et al. (2017). The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One 12(7):e0180355. DOI · PubMed 28700715

  • Network meta-analysis

    ADHD medicines (class): dose

    An analysis of how benefit changes with dose (113 trials) found that, in children and teens, extra benefit stopped rising above about 45 mg/day of methylphenidate, 25 mg/day of amphetamines and 4 mg/day of guanfacine, although data at higher doses were thin. Stopping for side effects rose at higher amphetamine doses, and at methylphenidate doses above 50 mg/day in adults. No dose–benefit pattern was found for atomoxetine in fixed-dose studies.

    Dose-effect NMA (Bayesian restricted cubic splines) of 113 double-blind RCTs: 68 pediatric (14,138 participants), 45 adult (11,016). Children/adolescents: median efficacy increased up to ~45 mg/day methylphenidate, ~25 mg/day amphetamines, ~4 mg/day guanfacine, with no evidence of added benefit above (wide credible intervals). Adults: amphetamines plateaued above ~50 mg/day; methylphenidate showed no plateau (sparse data). Dose-dependent AE-related discontinuation: amphetamines above 25 mg/day (children) and 50 mg/day (adults); methylphenidate above 50 mg/day in adults, no clear dose dependence in children. No dose-effect pattern for atomoxetine (fixed-dose studies) or modafinil. Needs full-text check: how amphetamine products were converted to a common dose scale is not stated in the abstract.

    Funding / affiliation: Non-industry (UK NIHR).

    Nourredine M, Jurek L, Hamza T, et al. (2026). Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis. Lancet Psychiatry 13(6):485-495. DOI · PubMed 42134365

  • Meta-analysis

    Amphetamines vs methylphenidate (class)

    A pooled analysis of 23 placebo-controlled trials in children and teens found that amphetamine products had somewhat larger average effects than methylphenidate products, even after adjusting for differences in study design. The trials did not compare the two directly.

    Meta-analysis/meta-regression of 23 double-blind placebo-controlled trials (11 drugs, 19 outcome measures). Effect sizes for amphetamine products were significantly, though moderately, greater than for methylphenidate products after correcting for design features. Indirect comparison (no head-to-head trials).

    Faraone SV, Buitelaar J (2010). Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19(4):353-64. DOI · PubMed 19763664

  • Network meta-analysis

    Adult ADHD treatments (class)

    In adults (113 trials), stimulants and atomoxetine were the only treatments that reduced core symptoms on both self-ratings and clinician ratings at 12 weeks. Several psychological approaches (such as CBT and mindfulness) helped only on clinician ratings. Atomoxetine and guanfacine were stopped more often than placebo.

    Component NMA, 113 RCTs (14,887 adults). 12-week core symptoms: atomoxetine SMD −0.38 self-rated (−0.56 to −0.21), −0.51 clinician-rated (−0.64 to −0.37); stimulants about −0.39 self-rated (CI −0.52 to −0.26) and −0.61 clinician-rated (−0.71 to −0.51). CBT (−0.76), cognitive remediation, mindfulness, psychoeducation and tDCS beat placebo on clinician-rated measures only. Acceptability worse than placebo: atomoxetine OR 1.43 (1.14–1.80), guanfacine 3.70 (1.22–11.19).

    Ostinelli EG, Schulze M, Zangani C, et al. (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Lancet Psychiatry 12(1):32-43. DOI · PubMed 39701638

  • Meta-analysis

    Methylphenidate vs atomoxetine (children)

    Combining nine head-to-head trials (2,762 participants), methylphenidate and atomoxetine did not differ overall in effect or response rates. In a subgroup, long-acting OROS methylphenidate (the Concerta-type formulation) worked better than atomoxetine, while immediate-release methylphenidate did not.

    Meta-analysis of 9 RCTs (n=2,762) comparing methylphenidate and atomoxetine. Overall SMD 0.09 (95% CI −0.08 to 0.26), NS; response RR 0.93 (0.76–1.14). Subgroup: OROS methylphenidate SMD 0.32 (0.12–0.53) favoring OROS; immediate-release methylphenidate −0.04 (−0.19 to 0.12). An update (Rezaei 2016, PMID 27390695; 11 studies, 2,772) reported the same pattern (OROS SMD 0.31, 0.16–0.47).

    Hanwella R, Senanayake M, de Silva V (2011). Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 11:176. DOI · PubMed 22074258

    See also: Rezaei G, Hosseini SA, Akbari Sari A, et al. (2016). Med J Islam Repub Iran. PubMed 27390695

Long-term real-world outcomes (5 studies)
  • Cohort / registry study

    ADHD medicines (class): risk of death

    In a Swedish national study of 148,578 people aged 6 to 64 newly diagnosed with ADHD, those who started ADHD medicine had a lower risk of dying over the next 2 years (39 vs 48 deaths per 10,000 people). The difference came mainly from fewer deaths from unnatural causes such as injuries, accidental poisonings and suicide; deaths from natural causes did not differ significantly. This is an observational study: it shows an association, not proof that the medicine caused the difference.

    Target trial emulation, Swedish registers (diagnosis 2007–2018; 2-year follow-up); n=148,578, of whom 84,204 (56.7%) started medication within 3 months. 2-year mortality 39.1 vs 48.1 per 10,000 (risk difference −8.9; 95% CI −17.3 to −0.6). All-cause HR 0.79 (0.70–0.88); unnatural-cause HR 0.75 (0.66–0.86); natural-cause HR 0.86 (0.71–1.05), not significant. Class-level estimate (all ADHD medicines); the abstract does not report methylphenidate separately.

    Li L, Zhu N, Zhang L, et al. (2024). ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA 331(10):850-860. DOI · PubMed 38470385

  • Cohort / registry study

    ADHD medicines (class; 88% started on methylphenidate)

    Using the same Swedish registers (148,581 people aged 6 to 64 newly diagnosed with ADHD), starting ADHD medicine was linked over 2 years to fewer first episodes of suicidal behavior (about 17% fewer), substance misuse (15%), transport accidents (12%) and criminal offenses (13%). Accidental injuries were not significantly reduced for first events, but repeat events of all five kinds were lower. Methylphenidate was the first medicine for 88% of people who started treatment. Observational: an association, not proof.

    Target trial emulation, Swedish registers 2007–2020; n=148,581; 84,282 (56.7%) initiated treatment, methylphenidate in 74,515 (88.4%). First events, adjusted IRR: suicidal behaviour 0.83 (95% CI 0.78–0.88); substance misuse 0.85 (0.83–0.87); transport accidents 0.88 (0.82–0.94); criminality 0.87 (0.83–0.90); accidental injuries 0.98 (0.96–1.01), not significant. Recurrent events: all five reduced (IRR 0.75–0.96). Class-level estimates.

    Zhang L, Zhu N, Sjölander A, et al. (2025). ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ 390:e083658. DOI · PubMed 40803836

  • Self-controlled case series

    ADHD medicines (class): changes over time

    A Swedish study of 247,420 people who used ADHD medicine between 2006 and 2020 compared periods on and off medicine in the same people. Medicine periods were consistently linked to fewer self-harm events, unintentional injuries, traffic crashes and crimes. However, the links for injuries, crashes and crime became weaker over time as the share of people taking ADHD medicine rose from 0.6% to 2.8%.

    Self-controlled case series, Swedish registers, ages 4–64, n=247,420; periods 2006–2010, 2011–2015 and 2016–2020 (medication prevalence 0.6% to 2.8%). Medicated vs non-medicated IRR ranges: self-harm 0.77 (0.73–0.81) to 0.85 (0.82–0.88); unintentional injury 0.87 (0.84–0.89) to 0.93 (0.91–0.95); traffic crashes 0.71 (0.67–0.77) to 0.87 (0.83–0.91); crime 0.73 (0.71–0.75) to 0.84 (0.82–0.85). Weakening over time for injury, crashes and crime (P for trend <.01), not fully explained by changes in age and sex mix.

    Li L, Coghill D, Sjölander A, et al. (2025). Increased Prescribing of Attention-Deficit/Hyperactivity Disorder Medication and Real-World Outcomes Over Time. JAMA Psychiatry 82(8):830-837. DOI · PubMed 40560574

  • Cohort / registry study

    ADHD medicines (class): criminal convictions

    Comparing the same 25,656 people with ADHD in Sweden during periods on and off medicine (2006–2009), criminal convictions were 32% lower in men and 41% lower in women while they were taking ADHD medicine. This links treatment with fewer crimes but cannot prove the medicine caused the drop.

    Swedish registers 2006–2009, n=25,656; stratified (within-individual) Cox regression, medicated vs non-medicated periods. Criminality: men adjusted HR 0.68 (95% CI 0.63–0.73); women HR 0.59 (0.50–0.70). Reductions of 17% to 46% in male sensitivity analyses (including by drug type, stimulant vs nonstimulant, and type of crime). Class-level estimate.

    Funding / affiliation: Non-industry (Swedish Research Council and others).

    Lichtenstein P, Halldner L, Zetterqvist J, et al. (2012). Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 367(21):2006-14. DOI · PubMed 23171097

  • Cohort / registry study

    ADHD medicines (class): serious transport accidents

    Following 17,408 people with ADHD in Sweden from 2006 to 2009, men had 58% fewer serious transport accidents (emergency visits or deaths) during periods when they were taking ADHD medicine than when they were not. No significant difference was found in women.

    Swedish registers 2006–2009, n=17,408. ADHD vs no ADHD, serious transport accidents: men adjusted HR 1.47 (95% CI 1.32–1.63), women 1.45 (1.24–1.71). Within-individual comparison of medicated vs non-medicated periods: men HR 0.42 (0.23–0.75); women not statistically significant. The authors estimated that 41% to 49% of accidents in men with ADHD might have been avoided with treatment throughout follow-up (a modelled estimate). Class-level estimate.

    Chang Z, Lichtenstein P, D'Onofrio BM, et al. (2014). Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry 71(3):319-25. DOI · PubMed 24477798

Heart and blood pressure (10 studies)
  • Meta-analysis

    Methylphenidate, amphetamines, atomoxetine (children)

    Pooling 18 trials in 5,837 children and teens, methylphenidate, amphetamines and atomoxetine all raised systolic blood pressure slightly on average. Amphetamines and atomoxetine also raised heart rate and diastolic pressure; methylphenidate did not. About 2% stopped because of heart-related effects. The authors advise regular heart rate and blood pressure checks.

    Systematic review/meta-analysis, 18 trials (10 MPH, 5 AMP, 7 ATX), n=5,837, mean 28.7 weeks. Pre–post SBP SMD: MPH 0.25 (0.08–0.42), AMP 0.09 (0.03–0.15), ATX 0.16 (0.04–0.27). DBP: AMP 0.16 (0.03–0.29), ATX 0.22 (0.10–0.34); HR: AMP 0.37 (0.13–0.60), ATX 0.43 (0.26–0.60); MPH no pre–post effect on DBP or HR. No significant head-to-head differences. 2% discontinued for any cardiovascular effect.

    Hennissen L, Bakker MJ, Banaschewski T, et al. (2017). Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs 31(3):199-215. DOI · PubMed 28236285

  • Network meta-analysis

    ADHD medicines (class)

    Pooling 102 short-term trials, most ADHD medicines raised blood pressure and pulse modestly, and stimulants did not raise them more than atomoxetine or viloxazine. Guanfacine lowered blood pressure and pulse. The authors advise monitoring blood pressure and pulse with any ADHD medicine, not just stimulants.

    NMA of 102 RCTs (13,315 children/adolescents; 9,387 adults; median 7 weeks). Children, mean increase vs placebo: SBP 1.07 (atomoxetine) to 1.81 mm Hg (methylphenidate); DBP 1.93 (amphetamines) to 2.42 (methylphenidate); pulse 2.79 bpm (viloxazine) to 5.58 bpm (atomoxetine). Amphetamines, lisdexamfetamine and methylphenidate not associated with larger increments than atomoxetine or viloxazine. Guanfacine in children: SBP −2.83 (−3.8 to −1.85), DBP −2.08, pulse −4.06. Only four RCTs informed medium-term effects. CINeMA confidence mostly low to moderate in children, very low in adults.

    Funding / affiliation: Non-industry (UK NIHR).

    Farhat LC, Lannes A, Del Giovane C, et al. (2025). Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 12(5):355-365. DOI · PubMed 40203844

  • Meta-analysis

    Methylphenidate and atomoxetine

    Pooling 22 studies (46,107 people), methylphenidate raised heart rate and systolic blood pressure compared with placebo in young people and adults; in children, atomoxetine raised them more than methylphenidate. Serious cardiac events did not differ.

    Meta-analysis/meta-regression of 22 studies (n=46,107). MPH vs placebo: greater pre–post HR (p<0.001) and SBP (p<0.001) increases in youth and adults. Children/adolescents: ATX > MPH for HR (p=0.025) and SBP (p<0.001). Moderators: age, dose, duration. No difference in adverse cardiac events (MPH vs placebo or ATX). Effects reported as standardized differences, not bpm/mm Hg, in the abstract.

    Liang EF, Lim SZ, Tam WW, et al. (2018). The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression. Int J Environ Res Public Health 15(8). DOI · PubMed 30127314

  • Case-control study

    ADHD medicines (class), long-term use

    In a Swedish registry study of 278,027 people with ADHD (ages 6–64), longer total use of ADHD medicine was linked to a higher risk of cardiovascular disease, about 4% more per year of use, mainly high blood pressure and arterial disease. This kind of study shows an association, not proof of cause.

    Nested case-control (Swedish registers, 2007–2020): 10,388 CVD cases vs 51,672 matched controls. Cumulative use vs non-use: 3–≤5 y AOR 1.27 (1.17–1.39); >5 y 1.23 (1.12–1.36). Per year of use AOR 1.04 (1.03–1.05), steeper in first 3 years (1.08). Hypertension 3–≤5 y AOR 1.72 (1.51–1.97), >5 y 1.80 (1.55–2.08). Similar in under-25s and adults. Not broken down by individual drug in the abstract.

    Zhang L, Li L, Andell P, et al. (2024). Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry 81(2):178-187. DOI · PubMed 37991787

  • Self-controlled case series

    Methylphenidate (all forms)

    A South Korean study of 1,224 children and teens who had a heart-related event while on methylphenidate found a higher rate of heart rhythm problems during treatment periods, and a higher rate of heart attack in the first weeks after starting. Absolute risk is likely low. No increase was seen for high blood pressure, stroke or heart failure.

    Nationwide self-controlled case series (2008–2011), 1,224 patients ≤17 y with an incident CV event and methylphenidate exposure. Arrhythmia IRR 1.61 (95% CI 1.48–1.74) across exposed periods, highest with congenital heart disease. Myocardial infarction 1.33 (0.90–1.98) overall, elevated in the early 8–56 day window. No significant increase for hypertension, ischaemic stroke or heart failure.

    Shin JY, Roughead EE, Park BJ, et al. (2016). Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ 353:i2550. DOI · PubMed 27245699

  • Cohort / registry study

    Methylphenidate (all forms)

    In a large Taiwanese cohort of 224,732 people with ADHD, methylphenidate users did not have a higher risk of major cardiovascular events than non-users over the study period.

    Propensity-matched cohort: 224,732 patients. Major CV events, MPH >7 days vs non-users HR 0.85 (0.72–0.99); >180 days 0.83 (0.69–1.00). Authors call for more evidence on long-term use.

    Liao HC, Hsu CN, Lin FJ, et al. (2024). Association between methylphenidate use and long-term cardiovascular risk in paediatric patients with attention deficit and hyperactivity disorder. BMJ Paediatr Open 8(1). DOI · PubMed 39231572

  • Case-control study

    Methylphenidate (all forms)

    A Danish general-population study (median age 72 among cardiac arrest cases) found methylphenidate use was linked to higher odds of out-of-hospital cardiac arrest, especially in the first 6 months after starting. Few users were in the study, and most were much older than typical ADHD patients.

    Nested case-control: 46,578 OHCA cases (median 72 y) vs 232,890 matched controls; MPH used by 80 cases, 166 controls. OR 1.78 (1.32–2.40); recent starters ≤180 days 2.59 (1.28–5.23). Persisted in those without hospital-diagnosed ADHD.

    Eroglu TE, Halili A, Arulmurugananthavadivel A, et al. (2023). Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study. Eur Heart J Cardiovasc Pharmacother 9(7):658-665. DOI · PubMed 37070942

  • Clinical practice guideline

    Stimulants and nonstimulants (children and teens)

    The 2019 American Academy of Pediatrics guideline says stimulants have not been shown to raise the risk of sudden death. Before starting, clinicians should ask about heart symptoms and a family history of sudden death or inherited heart rhythm or muscle conditions, and arrange further evaluation if any risk factor is present. It describes an ECG as part of that extra evaluation for nonstimulants when risk factors are present.

    AAP clinical practice guideline (Wolraich 2019), full text: obtain history of specific cardiac symptoms and family history of sudden death, cardiovascular symptoms, WPW, HCM and long QT before stimulants; if risk factors are present, obtain additional evaluation. For nonstimulants with risk factors, the additional evaluation is described as an ECG, with pediatric cardiology referral if abnormal. No routine ECG is recommended for patients without risk factors.

    Wolraich ML, Hagan JF Jr, Allan C, et al. (2019). Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics 144(4). DOI · PubMed 31570648

  • Clinical practice guideline

    ADHD medicines (class)

    The European ADHD Guidelines Group found no evidence that a routine ECG before starting ADHD medicine adds benefit. It notes that the American Heart Association first suggested an ECG as standard in 2008 and then left it to the clinician’s judgment. A 2009 Canadian joint statement likewise recommends a careful history and examination, with an ECG or cardiology referral only when these suggest a problem.

    European Guidelines Group (EUNETHYDIS) review of adverse effects, full text: “no current evidence to suggest an incremental benefit for routine ECG assessment” before medication; AHA in 2008 initially recommended ECG as standard, then changed this to clinician discretion; ECG screening not considered cost-effective for preventing sudden death in the general pediatric population. Canadian Paediatric Society / Canadian Cardiovascular Society / CACAP joint statement (Warren 2009, abstract): thorough history and physical examination; no routine ECG screening or cardiac subspecialist consultation unless indicated by history or examination.

    Graham J, Banaschewski T, Buitelaar J, et al. (2011). European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20(1):17-37. DOI · PubMed 21042924

    See also: Warren AE, Hamilton RM, Bélanger SA, et al. (2009). Can J Cardiol. DOI · PubMed 19898693

  • Cohort / registry study

    Children with ADHD (screening ECG)

    At one U.S. center, 1,470 children with ADHD had a screening ECG. About 8% were read as abnormal, but heart disease was found in only 5 children (0.3%), so most abnormal results were false alarms. Finding each true case cost about $17,000 in testing.

    Retrospective review of screening ECGs in 1,470 patients <21 y with ADHD (Apr–Sep 2008): 119 abnormal (8.1%); follow-up included 63 echocardiograms, 5 stress tests, 9 Holters; cardiac disease in 5 (0.3%: ventricular pre-excitation 2, bicuspid aortic valve 2, secundum ASD 1); positive predictive value 4.2%; mean cost $58 per child and $17,162 per true positive. The authors note screening can find asymptomatic disease but with low PPV.

    Mahle WT, Hebson C, Strieper MJ (2009). Electrocardiographic screening in children with attention-deficit hyperactivity disorder. Am J Cardiol 104(9):1296-9. DOI · PubMed 19840580

Growth (6 studies)
  • Cohort / registry study

    Methylphenidate (all forms)

    In a German national health survey of 4,244 boys, methylphenidate use was linked to very low body-mass index in some age groups, but not to short stature or blood pressure changes. Numbers of treated boys were small.

    KiGGS survey analysis: 4,244 boys (MPH <12 months n=65; ≥12 months n=53; ADHD controls 320; non-ADHD 3,806). BMI ≤3rd percentile more likely in pre-pubertal boys with <12 months of MPH and pubertal/post-pubertal boys with ≥12 months. No association with low height (≤3rd percentile) or BP changes.

    McCarthy S, Neubert A, Man KKC, et al. (2018). Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). BMC Psychiatry 18(1):327. DOI · PubMed 30305167

  • Randomized controlled trial

    Stimulants (mostly OROS methylphenidate), children 5–12

    Children whose weight dropped after starting a stimulant were randomly assigned to medicine on school days only (a planned break on weekends and holidays), a daily high-calorie snack, or monthly checks. All three helped weight gain, but none of them sped up growth in height. Most families in the school-days-only group went back to giving the medicine after school because symptoms got worse.

    RCT, 230 children aged 5–12 starting stimulants (78%, mainly OROS-MPH) or behavioral treatment for 30 months; children with a BMI decline >0.5 z after 6 months (n=71) were randomized to monthly monitoring, drug holidays (medication limited to school days) or a 150-kcal daily supplement. Weight velocity rose after randomization across all arms (β=0.271, SE 0.027, p<.001); per actual use, supplementation (p<.01) and holidays (p<.05) increased weight velocity more than monitoring. No arm increased height velocity. Full text: parents gave medication on only 5% of weekend days in the holiday arm; 16 of 23 (70%) reverted to after-school dosing because of worsening symptoms.

    Waxmonsky JG, Pelham WE 3rd, Campa A, et al. (2020). A Randomized Controlled Trial of Interventions for Growth Suppression in Children With Attention-Deficit/Hyperactivity Disorder Treated With Central Nervous System Stimulants. J Am Acad Child Adolesc Psychiatry 59(12):1330-1341. DOI · PubMed 31473291

  • Randomized controlled trial

    Methylphenidate (immediate-release, twice daily)

    In a 4-week trial in boys taking methylphenidate twice a day, swapping in a placebo on weekends led to less trouble sleeping and a trend toward better appetite. ADHD symptoms on weekends (parent ratings) and on the following Monday (teacher ratings) did not rise significantly. The study was small and short.

    Double-blind RCT, 28 days, boys with ADHD: MPH b.i.d. 7 days/week (n=21) vs weekdays with weekend placebo (n=19). No significant group difference in parent weekend ratings (endpoint p=0.41, ES 0.26) or Monday teacher ratings (p=0.99, ES 0.002). Weekend placebo: less insomnia (F=3.96, p=0.05) and a trend to less appetite interference (F=3.18, p=0.08). Growth was not an outcome.

    Martins S, Tramontina S, Polanczyk G, et al. (2004). Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol 14(2):195-206. DOI · PubMed 15319017

  • Randomized controlled trial

    Methylphenidate (long-term use)

    Children on long-term methylphenidate were randomly assigned to stop or continue it over two summers. One summer off was followed by more weight gain but no height difference; two summers off had a significant positive effect on height. The study could not show whether this changes final adult height.

    Controlled withdrawal study: hyperactive children on long-term MPH randomized to be off or remain on medication over two consecutive summers. After one summer: no height difference, higher weight in the off-medication group. After two summers: significant positive effect on height (not weight). Authors note the results do not address long-term effects on height. Needs full-text check: sample size and effect sizes are not in the abstract.

    Klein RG, Landa B, Mattes JA, et al. (1988). Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry 45(12):1127-30. DOI · PubMed 3058088

  • Systematic review (narrative)

    ADHD medicines (mostly stimulants), children and teens

    A review of 22 studies from 1972 to 2013 found that 25–70% of families take breaks from ADHD medicine, most often during school holidays. Breaks are used to check whether medicine is still needed and to manage side effects. Longer breaks were linked to better growth, and shorter breaks could reduce sleep problems and improve appetite.

    Literature review (22 studies, 1972–2013) of drug holidays in children and adolescents. Prevalence 25–70% of families, more often in school holidays; purposes: testing ongoing need, managing adverse effects and tolerance. Positive impact on growth with longer breaks; shorter breaks could reduce insomnia and improve appetite. Study quality not graded in the abstract.

    Ibrahim K, Donyai P (2015). Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades. J Atten Disord 19(7):551-68. DOI · PubMed 25253684

  • Cohort / registry study

    Stimulants (MTA follow-up into adulthood)

    In the long-term follow-up of the MTA study, young adults who had taken stimulants consistently through childhood were on average about 2.4 cm shorter than those who took them inconsistently, and treated groups were about 2.6 cm shorter than those who took little or none. Consistent long-term use was not linked to fewer adult ADHD symptoms. These groups were not randomized.

    Observational follow-up of the MTA (579 randomized; 515 followed; 289 classmates as local norms), outcomes at ~25 years. Adult height: Consistent/Inconsistent users 2.55 ± 0.73 cm shorter than Negligible users (p<.0005); Consistent 2.36 ± 1.13 cm shorter than Inconsistent (p<.04). Naturalistic-subgroup comparisons for symptom severity were not significant. Full text: height was measured in 402 ADHD participants (Consistent subgroup n=33).

    Swanson JM, Arnold LE, Molina BSG, et al. (2017). Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry 58(6):663-678. DOI · PubMed 28295312

Psychosis and mania (6 studies)
  • Cohort / registry study

    Amphetamine vs methylphenidate

    In US insurance data on 221,846 adolescents and young adults (13–25) starting a stimulant, new psychosis treated with an antipsychotic occurred in about 1 in 660. It was about twice as common with amphetamine (0.21%) as with methylphenidate (0.10%).

    Propensity-matched cohort (2 claims databases, 2004–2015): 110,923 MPH vs 110,923 amphetamine starters. 343 psychosis episodes: 106 (0.10%) MPH vs 237 (0.21%) amphetamine; HR 1.65 (95% CI 1.31–2.09) for amphetamine.

    Funding / affiliation: Non-industry (NIMH and others).

    Moran LV, Ongur D, Hsu J, et al. (2019). Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. N Engl J Med 380(12):1128-1138. DOI · PubMed 30893533

  • Case-control study

    Amphetamines (class)

    Among young people hospitalized for psychiatric reasons, recent prescription amphetamine use was linked to higher odds of a first episode of psychosis or mania, and the link was strongest at higher doses (above 30 mg of dextroamphetamine-equivalent). Recent methylphenidate use was not linked. Because only hospitalized patients were compared, results may not apply to everyone.

    Case-control (McLean Hospital EHR, 2005–2019): 1,374 cases (incident psychosis/mania, ages 16–35) vs 2,748 psychiatric controls. Past-month amphetamine aOR 2.68 (1.90–3.77); >30 mg dextroamphetamine equivalents ~5.28-fold. Methylphenidate aOR 0.91 (0.54–1.55). Selection bias acknowledged.

    Moran LV, Skinner JP, Shinn AK, et al. (2024). Risk of Incident Psychosis and Mania With Prescription Amphetamines. Am J Psychiatry 181(10):901-909. DOI · PubMed 39262211

  • Meta-analysis

    Methylphenidate (all forms)

    A Cochrane-method review could not confirm or rule out that methylphenidate causes psychotic symptoms such as hallucinations in children. Such symptoms were reported in roughly 1 to 2.5 of every 100 children in the available studies, and families should know to report them.

    Systematic review: 10 RCTs (1,103 participants), 17 non-randomised studies, 12 case reports/series. RCTs: 10/654 MPH vs 1/508 placebo, RR 2.07 (0.58–7.35), underpowered, 9/10 high risk of bias. Non-randomised pooled prevalence 1.2% (0.7–2.4). One comparative cohort RR 1.36 (1.17–1.57), critical risk of bias. Possible frequency 1.1–2.5%.

    Ramstad E, Storebø OJ, Gerner T, et al. (2018). Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis(). Scand J Child Adolesc Psychiatr Psychol 6(1):52-71. DOI · PubMed 33520751

  • Meta-analysis

    Stimulants in ADHD (class): psychosis and bipolar disorder

    Pooling 16 studies of about 391,000 people with ADHD, a 2025 review estimated that roughly 2% to 4% of people treated with stimulants later had psychotic symptoms, a psychotic disorder or bipolar disorder, although results varied widely between studies. Psychosis was more common with amphetamines than with methylphenidate. These studies cannot show that the medicine caused the problems, and the authors advise discussing these risks and watching for them during treatment.

    Systematic review and meta-analysis (searches to Oct 1, 2024), 16 studies, N=391,043 (mean age 12.6 y). Pooled occurrence among stimulant-treated individuals: psychotic symptoms 2.76% (95% CI 0.73–9.88; k=10), psychotic disorder 2.29% (1.52–3.40; k=4), bipolar disorder 3.72% (0.77–16.05; k=4); heterogeneity I² >95%. Psychosis, amphetamines vs methylphenidate: OR 1.57 (1.15–2.16; k=3, n=231,325). Higher occurrence in North American studies, with longer follow-up, more female participants, smaller samples and higher stimulant doses. Observational data; causality not established.

    Salazar de Pablo G, Aymerich C, Chart-Pascual JP, et al. (2025). Occurrence of Psychosis and Bipolar Disorder in Individuals With Attention-Deficit/Hyperactivity Disorder Treated With Stimulants: A Systematic Review and Meta-Analysis. JAMA Psychiatry 82(11):1103-1112. DOI · PubMed 40900605

  • Cohort / registry study

    Methylphenidate in adults with bipolar disorder

    In Swedish national registers, 2,307 adults with bipolar disorder started methylphenidate. Those taking it without a mood stabilizer had a much higher rate of mania in the next 3 months, while those also taking a mood stabilizer did not; their rate was lower than before. The authors advise checking carefully for bipolar disorder before starting a stimulant on its own.

    Linked Swedish registers, 2006–2014; n=2,307 adults with bipolar disorder starting methylphenidate. Within-individual Cox regression comparing mania (hospitalization or new mood-stabilizer dispensing) 0–3 months after start with untreated periods. Methylphenidate monotherapy: HR 6.7 (95% CI 2.0–22.4), similar for months 3–6. With a mood stabilizer: HR 0.6 (0.4–0.9). Similar results counting only hospitalizations for mania.

    Viktorin A, Rydén E, Thase ME, et al. (2017). The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. Am J Psychiatry 174(4):341-348. DOI · PubMed 27690517

  • Cohort / registry study

    Methylphenidate in adults with bipolar disorder (French replication)

    A French national claims study tried to repeat the Swedish findings. In 3,526 adults with bipolar disorder who were taking a mood stabilizer, methylphenidate was not linked to more mania, except at doses above 30 mg. In 2,745 people not taking a mood stabilizer, mania was more common in the 3 months after starting, but that link disappeared in a stricter analysis, and the authors think it may reflect the natural course of the illness.

    French national claims database (SNDS), 2008–2024; self-controlled survival analysis of manic relapse in the 6 months before vs after a new methylphenidate dispensation. No mood stabilizer (n=2,745): inpatient mania diagnoses significantly higher within 3 months, not significant in self-controlled case-crossover analyses. Continuous mood stabilizer (n=3,526): no significant change except at >30 mg methylphenidate. Using new antimanic therapy as the outcome gave outlier results. Effect sizes are not given in the abstract.

    Vidal N, Frileux S, Younes N, et al. (2026). Methylphenidate and manic relapse in bipolar disorders: A replication study in a nationwide claims database. J Psychopharmacol 2698811261443684. DOI · PubMed 42132544

ADHD with other conditions (1 study)
  • Meta-analysis

    ADHD with tic disorders

    In children with ADHD and tics (9 trials), methylphenidate, alpha-2 agonists (clonidine, guanfacine) and atomoxetine improved ADHD symptoms. Alpha-2 agonists and atomoxetine also reduced tics, and methylphenidate did not worsen tics in the short term. Very high doses of dextroamphetamine were linked to worse tics.

    Meta-analysis, 9 studies, 477 subjects. ADHD efficacy: MPH, α2 agonists, desipramine, ATX. Tic improvement: α2 agonists and ATX. No evidence MPH worsened tics short-term; supratherapeutic dextroamphetamine worsened tics. Authors: MPH gave the greatest and most immediate ADHD improvement.

    Bloch MH, Panza KE, Landeros-Weisenberger A, et al. (2009). Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 48(9):884-893. DOI · PubMed 19625978

Pregnancy (5 studies)

These research findings do not replace the FDA label. For what the label says, see Pregnancy and breastfeeding above.

  • Cohort / registry study

    Methylphenidate and amphetamines

    In very large US and Nordic pregnancy registries, first-trimester methylphenidate was linked to a small increase in heart defects (about 28% higher relative risk), while amphetamines were not linked to more birth defects. Absolute risks remained low.

    Cohort: 1,813,894 US Medicaid pregnancies; Nordic replication 2,560,069. US adjusted RR, MPH: any malformation 1.11 (0.91–1.35), cardiac 1.28 (0.94–1.74); amphetamines: any 1.05 (0.93–1.19), cardiac 0.96 (0.78–1.19). Pooled US+Nordic MPH cardiac RR 1.28 (1.00–1.64). US cardiac risk per 1,000: 12.7 unexposed, 18.8 MPH, 15.4 amphetamines.

    Huybrechts KF, Bröms G, Christensen LB, et al. (2018). Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. JAMA Psychiatry 75(2):167-175. DOI · PubMed 29238795

  • Meta-analysis

    Stimulants and atomoxetine in pregnancy

    A 2026 review of 25 studies found that, after accounting for differences between mothers, using stimulants or atomoxetine in pregnancy was not linked to more major birth defects or to most pregnancy and child-development problems. A small link with methylphenidate and heart defects, and with a low newborn Apgar score, could not be ruled out and needs more study.

    Systematic review/meta-analysis (25 studies; 23 pooled). Major malformations: unadjusted RR 1.25 (1.14–1.37), adjusted 1.04 (0.97–1.12). Cardiovascular malformations aRR 1.20 (0.88–1.63); methylphenidate-specific aRR 1.33 (1.01–1.74). No adjusted association with miscarriage, preterm birth, low birth weight, SGA, NICU admission or offspring neurodevelopmental disorders. Low 5-min Apgar aRR 1.21 (1.03–1.42). Authors attribute crude associations largely to confounding.

    Komargodski R, Tillawe A, Berlin M, et al. (2026). Pregnancy and Offspring Outcomes After Prenatal Stimulant or Atomoxetine Exposure: A Systematic Review and Meta-analysis. Am J Obstet Gynecol MFM 102165. DOI · PubMed 42887725

  • Cohort / registry study

    Methylphenidate (all forms)

    A Danish registry study of 364,012 pregnancies found methylphenidate in early pregnancy was not linked to more birth defects overall, but there was a possible increase in heart defects (mostly holes between heart chambers).

    Registry cohort (2007–2014) using prenatal and postnatal diagnoses. MPH adjusted PR: malformations overall 1.04 (0.70–1.55); any cardiac 1.65 (0.89–3.05; NNH 92); ventricular septal defect 2.74 (1.03–7.28); severe cardiac 2.59 (0.98–6.90).

    Kolding L, Ehrenstein V, Pedersen L, et al. (2021). Associations Between ADHD Medication Use in Pregnancy and Severe Malformations Based on Prenatal and Postnatal Diagnoses: A Danish Registry-Based Study. J Clin Psychiatry 82(1). DOI · PubMed 33406323

  • Meta-analysis

    Methylphenidate and atomoxetine in pregnancy

    Pooling 10 observational studies, birth defects and miscarriage were not more common in babies of mothers who took methylphenidate or atomoxetine in pregnancy than in unexposed babies.

    Meta-analysis of 10 observational studies. vs unexposed offspring of mothers with ADHD: congenital anomalies OR 1.14 (0.83–1.55), miscarriage 1.01 (0.70–1.47); vs general population: anomalies 1.19 (0.93–1.53; I² 74%), miscarriage 1.05 (0.81–1.37). Preterm birth and birth weight not reported as outcomes in the abstract.

    di Giacomo E, Confalonieri V, Tofani F, et al. (2024). Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-Analysis. JAMA Netw Open 7(11):e2443648. DOI · PubMed 39504019

  • Meta-analysis

    ADHD medicines in pregnancy (class)

    Pooling 8 cohort studies, ADHD medicine during pregnancy was linked to more newborn intensive-care admissions but not to other maternal or newborn problems; methylphenidate showed a borderline link with heart defects.

    Meta-analysis of 8 cohorts. NICU admission RR 1.88 (1.7–2.08) vs never exposed; 1.38 (1.23–1.54) vs exposure before/after pregnancy only. MPH and cardiac malformation RR 1.27 (0.99–1.63; p=0.065). No association with other outcomes; limited confounder adjustment.

    Jiang HY, Zhang X, Jiang CM, et al. (2019). Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 28(3):288-295. DOI · PubMed 30585374

Frequently asked questions

How long does Quillivant XR last?

In a children’s classroom study, it worked better than placebo at time points from 45 minutes through 12 hours after the morning dose.

Why do I have to shake Quillivant XR?

The medicine is a suspension, so it settles. The label says to shake the bottle vigorously for at least 10 seconds before every dose so each dose is correct.

How long is Quillivant XR good after it is mixed?

The reconstituted suspension is stable for up to 4 months when stored at room temperature.

How much liquid is a 20 mg dose?

Quillivant XR contains 25 mg per 5 mL, so 20 mg is 4 mL. Always follow the dose on your prescription label and use the oral dosing dispenser provided.

Is there a generic Quillivant XR?

Sources disagree. The FDA Orange Book lists an AB-rated generic from Actavis (Teva), approved in 2018, as an active prescription product, but as of Oct 29, 2026 neither the FDA NDC Directory nor DailyMed lists it, and ASHP lists only the brand. Ask your pharmacy which versions it can currently order.

Can Quillivant XR be taken with food?

Yes. It can be taken with or without food.

How is Quillivant XR different from Methylin?

Methylin is a short-acting solution taken 2–3 times a day. Quillivant XR is a long-acting suspension taken once daily.

Is Quillivant XR in shortage?

No shortage is listed. ASHP (updated Oct 14, 2026; checked Oct 29, 2026) lists Quillivant XR as available, and the FDA Drug Shortages database has no entry for it. Ask your pharmacy to confirm stock.

How quickly does Quillivant XR start working?

In the label’s classroom study, Quillivant XR was better than placebo at 45 minutes after the dose, the earliest time checked, and at 2, 4, 8, 10 and 12 hours (label section 14). Blood levels peak about 4 to 5 hours after the dose (label section 12.3).

Does Quillivant XR cause a crash or rebound as it wears off?

The Quillivant XR label does not describe a “crash” or rebound effect. In its classroom study, benefit was still significant 12 hours after the dose (label section 14). Irritability and mood swings are among the common side effects listed in the Medication Guide.If ADHD symptoms, irritability or tiredness come back as a dose wears off, tell your prescriber; the timing or dose may need adjusting.

What should I do if I miss a dose of Quillivant XR?

The Quillivant XR label does not give specific missed-dose steps; the Medication Guide says to talk to your health care provider about dosing if a dose is missed.

What are the most common side effects of Quillivant XR?

The Medication Guide lists decreased appetite, trouble sleeping, nausea, vomiting, indigestion, stomach pain, weight loss, anxiety, dizziness, irritability, mood swings, fast heartbeat and increased blood pressure (label section 6.1). These are not all the possible side effects; call your prescriber for advice about side effects that bother you.

Is an ECG (heart tracing) needed before starting?

Usually not. Before prescribing, the clinician should ask about fainting, chest pain, a racing heartbeat, known heart problems, and any family history of sudden death or heart rhythm problems, and do a physical exam. An ECG or a visit to a heart specialist is used when any of these raise concern. UK, Canadian and European guidance does not call for a routine ECG when there are no such warning signs.

Can my child take breaks from the medicine on weekends or over the summer?

Sometimes, but plan it with the prescriber. Breaks can help with appetite, weight gain and sleep, and the label says children who are not growing or gaining weight as expected may need treatment paused. Breaks have not been shown to reliably make children taller, and ADHD symptoms can come back on days off, so it depends on how much your child struggles without the medicine. A break can also show whether the medicine is still needed.

Can I take Quillivant XR while pregnant or breastfeeding?

Tell your clinician if you are pregnant or planning a pregnancy. There is not enough information to know whether methylphenidate raises the risk of birth defects, miscarriage, or other problems in pregnancy. The Quillivant XR label says small amounts of methylphenidate pass into breast milk; if you breastfeed, decide together with your clinician and watch the baby for agitation, poor sleep, poor feeding, or slow weight gain. A pregnancy registry for ADHD medicines can be reached at 1-866-961-2388.

Prescribing guidelines

Methylphenidate-class extended-release formulations are first-line pharmacologic options for school-age children and adolescents per major guidelines when medication is indicated.

Sources

  • Tris Pharma, Inc. (SPL labeler NextWave Pharmaceuticals, Inc.). Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII. Prescribing Information, revised 03/2026. DailyMed (accessed Oct 2026).
  • U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), data files dated October 2026 (products file dated Oct 9, 2026; rechecked with the Orange Book web search Oct 29, 2026). FDA; Orange Book search.
  • National Library of Medicine. DailyMed SPL search: methylphenidate extended-release oral suspension (database published Oct 28, 2026; accessed Oct 29, 2026). DailyMed.
  • U.S. Food and Drug Administration. National Drug Code Directory (openFDA drug/ndc endpoint), methylphenidate extended-release oral suspension listings; data updated Oct 28, 2026; accessed Oct 29, 2026. FDA NDC Directory.
  • U.S. Food and Drug Administration. Drug Shortages database, accessed Oct 29, 2026. FDA.
  • American Society of Health-System Pharmacists. Drug Shortage Detail: Methylphenidate Extended Release Oral Presentations. Updated Oct 14, 2026 (accessed Oct 29, 2026). ASHP.
  • Wolraich ML, Hagan JF Jr, Allan C, et al.; American Academy of Pediatrics Subcommittee on Children and Adolescents with ADHD. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. AAP.
  • Centers for Disease Control and Prevention. Clinical Care of ADHD in Children (summary of the AAP guideline; updated Oct 21, 2026). CDC (accessed 2026).
  • Drugs and Lactation Database (LactMed). Methylphenidate. National Institute of Child Health and Human Development; revised Aug 2025. NCBI Bookshelf NBK501310.
  • National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management (NG87), 2018, updated 2019; recommendations 1.7.3–1.7.5, 1.7.20–1.7.22, 1.8.6–1.8.7 and 1.10.3. NICE (accessed Oct 2026).
  • Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921. PubMed 17581453.
  • Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021, NSDUH Series H-59), 2024. SAMHSA (accessed Nov 9, 2026).
EDUCATIONAL INFORMATION ONLY. Not medical advice. Graphs are schematic illustrations based on publicly available labeling and are not to clinical scale. Availability status is reviewed periodically and may change. Medication decisions require individualized assessment by a qualified clinician. Brand logos are trademarked; official use requires permission. Full medical disclaimer · Privacy
Back to top